Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HRS9531 versus placebo in adults with type 2 diabetes inadequately controlled on basal insulin
CTR20252475Phase 3Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2025; status: active.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20252475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252475.